Short-Term Administration of Serelaxin Produces Predominantly Vascular Benefits in the Angiotensin II/L-NAME Chronic Heart Failure Model

Short-Term Administration of Serelaxin Produces Predominantly Vascular Benefits in the Angiotensin II/L-NAME Chronic Heart Failure Model

Summary: In patients hospitalized with acute heart failure, temporary serelaxin infusion reduced 6-month mortality through unknown mechanisms. This study therefore explored the cardiovascular effects of temporary serelaxin administration in mice subjected to the angiotensin II (AngII)/L-NG-nitroargi...

Full description

Bibliographic Details
Main Authors: Joseph C. McCarthy, MS, Mark Aronovitz, MS, Jennifer J. DuPont, PhD, Timothy D. Calamaras, PhD, Iris Z. Jaffe, MD, PhD, Robert M. Blanton, MD
Format: Article
Language:English
Published: Elsevier 2017-06-01
Series:JACC: Basic to Translational Science
Online Access:http://www.sciencedirect.com/science/article/pii/S2452302X17300979
id doaj-c518624d4d9b48598e66f09100889075
record_format Article
spelling doaj-c518624d4d9b48598e66f091008890752020-11-25T00:52:42ZengElsevierJACC: Basic to Translational Science2452-302X2017-06-0123285296Short-Term Administration of Serelaxin Produces Predominantly Vascular Benefits in the Angiotensin II/L-NAME Chronic Heart Failure ModelJoseph C. McCarthy, MS0Mark Aronovitz, MS1Jennifer J. DuPont, PhD2Timothy D. Calamaras, PhD3Iris Z. Jaffe, MD, PhD4Robert M. Blanton, MD5Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MassachusettsMolecular Cardiology Research Institute, Tufts Medical Center, Boston, MassachusettsMolecular Cardiology Research Institute, Tufts Medical Center, Boston, MassachusettsMolecular Cardiology Research Institute, Tufts Medical Center, Boston, MassachusettsMolecular Cardiology Research Institute, Tufts Medical Center, Boston, MassachusettsAddress for correspondence: Dr. Robert M. Blanton, Tufts Medical Center, 800 Washington Street, Box 80 Boston, Massachusetts 02111.; Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MassachusettsSummary: In patients hospitalized with acute heart failure, temporary serelaxin infusion reduced 6-month mortality through unknown mechanisms. This study therefore explored the cardiovascular effects of temporary serelaxin administration in mice subjected to the angiotensin II (AngII)/L-NG-nitroarginine methyl ester (L-NAME) heart failure model, both during serelaxin infusion and 19 days postâserelaxin infusion. Serelaxin administration did not alter AngII/L-NAME-induced cardiac hypertrophy, geometry, or dysfunction. However, serelaxin-treated mice had reduced perivascular left ventricular fibrosis and preserved left ventricular capillary density at both time points. Furthermore, resistance vessels from serelaxin-treated mice displayed decreased potassium chlorideâinduced constriction and reduced aortic fibrosis. These findings suggest that serelaxin improves outcomes in patients through vascular-protective effects. Key Words: heart failure, relaxin, vascular functionhttp://www.sciencedirect.com/science/article/pii/S2452302X17300979
collection DOAJ
language English
format Article
sources DOAJ
author Joseph C. McCarthy, MS
Mark Aronovitz, MS
Jennifer J. DuPont, PhD
Timothy D. Calamaras, PhD
Iris Z. Jaffe, MD, PhD
Robert M. Blanton, MD
spellingShingle Joseph C. McCarthy, MS
Mark Aronovitz, MS
Jennifer J. DuPont, PhD
Timothy D. Calamaras, PhD
Iris Z. Jaffe, MD, PhD
Robert M. Blanton, MD
Short-Term Administration of Serelaxin Produces Predominantly Vascular Benefits in the Angiotensin II/L-NAME Chronic Heart Failure Model
JACC: Basic to Translational Science
author_facet Joseph C. McCarthy, MS
Mark Aronovitz, MS
Jennifer J. DuPont, PhD
Timothy D. Calamaras, PhD
Iris Z. Jaffe, MD, PhD
Robert M. Blanton, MD
author_sort Joseph C. McCarthy, MS
title Short-Term Administration of Serelaxin Produces Predominantly Vascular Benefits in the Angiotensin II/L-NAME Chronic Heart Failure Model
title_short Short-Term Administration of Serelaxin Produces Predominantly Vascular Benefits in the Angiotensin II/L-NAME Chronic Heart Failure Model
title_full Short-Term Administration of Serelaxin Produces Predominantly Vascular Benefits in the Angiotensin II/L-NAME Chronic Heart Failure Model
title_fullStr Short-Term Administration of Serelaxin Produces Predominantly Vascular Benefits in the Angiotensin II/L-NAME Chronic Heart Failure Model
title_full_unstemmed Short-Term Administration of Serelaxin Produces Predominantly Vascular Benefits in the Angiotensin II/L-NAME Chronic Heart Failure Model
title_sort short-term administration of serelaxin produces predominantly vascular benefits in the angiotensin ii/l-name chronic heart failure model
publisher Elsevier
series JACC: Basic to Translational Science
issn 2452-302X
publishDate 2017-06-01
description Summary: In patients hospitalized with acute heart failure, temporary serelaxin infusion reduced 6-month mortality through unknown mechanisms. This study therefore explored the cardiovascular effects of temporary serelaxin administration in mice subjected to the angiotensin II (AngII)/L-NG-nitroarginine methyl ester (L-NAME) heart failure model, both during serelaxin infusion and 19 days postâserelaxin infusion. Serelaxin administration did not alter AngII/L-NAME-induced cardiac hypertrophy, geometry, or dysfunction. However, serelaxin-treated mice had reduced perivascular left ventricular fibrosis and preserved left ventricular capillary density at both time points. Furthermore, resistance vessels from serelaxin-treated mice displayed decreased potassium chlorideâinduced constriction and reduced aortic fibrosis. These findings suggest that serelaxin improves outcomes in patients through vascular-protective effects. Key Words: heart failure, relaxin, vascular function
url http://www.sciencedirect.com/science/article/pii/S2452302X17300979
work_keys_str_mv AT josephcmccarthyms shorttermadministrationofserelaxinproducespredominantlyvascularbenefitsintheangiotensiniilnamechronicheartfailuremodel
AT markaronovitzms shorttermadministrationofserelaxinproducespredominantlyvascularbenefitsintheangiotensiniilnamechronicheartfailuremodel
AT jenniferjdupontphd shorttermadministrationofserelaxinproducespredominantlyvascularbenefitsintheangiotensiniilnamechronicheartfailuremodel
AT timothydcalamarasphd shorttermadministrationofserelaxinproducespredominantlyvascularbenefitsintheangiotensiniilnamechronicheartfailuremodel
AT iriszjaffemdphd shorttermadministrationofserelaxinproducespredominantlyvascularbenefitsintheangiotensiniilnamechronicheartfailuremodel
AT robertmblantonmd shorttermadministrationofserelaxinproducespredominantlyvascularbenefitsintheangiotensiniilnamechronicheartfailuremodel
_version_ 1725240795195244544

Similar Items